We have studied the use of clonidine combined with low doses of sufentanil and bupivacaine in 45 parturients requiring extradural analgesia for the first stage of labour, in a double-blind, randomized study. We gave 0.0625% bupivacaine 10 ml containing 1:200 000 adrenaline and sufentanil 10 g (1 ml) to which was added 0.9% saline, or clonidine 100 or 150 g (1 ml). We compared the quality (VAS scores) and duration of analgesia, motor block, maternal haemodynamic state (mean arterial pressure and heart rate) and fetal and maternal side effects. Mean duration of anaesthesia was prolonged slightly: 105 (SD 21) min without clonidine, 130 (26) min with clonidine 100 g (P:0.05 vs control) and 144 (40) min with clonidine 150 g (P:0.01 vs control, ns vs 100 g). There were no differences in VAS scores, onset times, heart rate, ventilatory frequency, motor block, sedation, pruritus or bradycardia between the groups. Analgesia was associated with a reduction in mean arterial pressure with clonidine. However, these adverse side effects were of minor clinical importance regardless of the extradural clonidine dose, except for a high incidence of fetal heart tracing abnormalities when clonidine 150 g was used.
Opioids are commonly combined with local anaesthetics to enhance extradural anaesthesia during labour 1 2 . Extradural clonidine, an alpha 2 adrenergic receptor agonist, produces analgesia without the motor block associated with high doses or concentrations of local anaesthetics 3 or side effects such as nausea, pruritus and risk of respiratory depression associated with the opioids 4 . Therefore, a combination of clonidine and opioids may be an attractive alternative for analgesia in labour but to date there have been no studies designed to assess the safety and efficacy of clonidine combined with low concentrations (:0.125%) of local anaesthetic during analgesia in labour.
The aim of this study was to evaluate the maternal, fetal and neonatal effects of clonidine 100 or 150 g administered extradurally in combination with 0.0625% bupivacaine and adrenaline 1:200 000 with sufentanil 10 g during the first stage of labour.
Patients and methods
The study was approved by the hospital Ethics Committee. After obtaining written consent, we studied 45 women, ASA I or II, with a singleton vertex pregnancy of at least 37 weeks' gestation, who requested extradural analgesia in labour. A sample size calculation was performed using the Instat computer software package (GraphPad Instat, San Diego, CA, USA). Power analysis showed that a sample size of 15 patients per treatment group should provide 95% power (assuming ␣:0.05) to detect a 30-min difference (SD) in duration of analgesia.
All patients had uncomplicated pregnancies and normal fetal heart tracings. We excluded patients receiving antihypertensive drugs, those with baseline heart rates :55 beat min 91 and patients who had already received opioid analgesia during this labour.
Each parturient received i.v. infusion of Ringer's lactate 500 ml over 10 min before induction of extradural anaesthesia and was positioned in the sitting position. The extradural space was cannulated at L2-3 or L3-4 using loss of resistance to saline (5 ml) and 3 cm of catheter was left in place. The parturient was then repositioned to lie with a left lateral tilt.
A double-blind, randomized study design was used. Parturients were allocated randomly according to a list of random numbers into three groups (sealed opaque envelopes). All injectates were prepared by an anaesthetist not involved in data collection.
Each syringe of coded study solution was prepared freshly. Each parturient received a test dose of 2% lignocaine 2 ml with 1:200 000 adrenaline. Five minutes later, each received a 12 ml solution comprising 0.0625% bupivacaine 10 ml with sufentanil 10 g (1 ml) to which was added clonidine 100 g, clonidine 150 g or 0.9% saline (1 ml). Bupivacaine 0.0625% solutions were prepared by diluting 0.25% solutions, without preservatives, with 0.9% saline and adrenaline was then added (1:200 000). Arterial pressure and heart rate were monitored with a non-invasive monitor (Cardiocap II, Datex, Helsinki) 5, 10, 20, 30, 40, 60, 80, 100 and 120 min after extradural injection, and then every 20 min until the need for an additional extradural anaesthetic injection. When additional analgesia was requested, the study was terminated. Subsequent top-up doses were not standardized, allowing the anaesthetist to use either 0.0625% or 0.125% bupivacaine as necessary.
Motor block (modified Bromage score
5
: 0:ability to move hips, ankles and knees; 1:inability to raise extended leg; 2:inability to flex knee; and 3:inability to flex ankle, foot or knee), sedation (1:wide awake, 2:dozing, 3:asleep, 4:unrousable), cephalic dermatomal level of anaesthesia (cold test), ventilatory frequency and oxyhaemoglobin saturation (pulse oximeter, Cardiocap II, Datex, Helsinki) were recorded at the same times. Basal values were those obtained immediately before extradural injection.
Pain was assessed on a linear visual analogue scale (VAS). Each patient was presented with a line 100 mm long and was told that the left end represented no pain and the right end the worst pain imaginable. They were asked to make a mark on the line to indicate the intensity of pain at the peak of a contraction. Patients could request additional analgesia (0.25% bupivacaine via the extradural catheter) if pain relief was unsatisfactory by 15 min after injection of the study drug. At the end of the study, both the patient and nurse made an overall global rating of the treatment (poor, fair, good, very good, excellent).
The time from administration of study drug to request for additional analgesia was noted (duration of analgesia). Side effects such as pruritus, nausea and vomiting were recorded at completion of the study. Bradycardia was defined as the occurrence of a maternal heart rate 960 beat min 91 and treated with atropine i.v. Hypotension, defined as a decrease in systolic arterial pressure of at least 20% or a systolic arterial pressure :100 mm Hg, was treated with i.v. ephedrine as necessary.
Continuous electronic cardiotocograph monitoring using an external transducer was used for all patients throughout labour (Hewlett Packard 80034 A). Tracings were analysed by an obstetrician who was unaware of which solution was being administered (F. G.). Analysis compared tracings obtained 30 min before extradural injection with those recorded during analgesia. Changes in baseline fetal heart rate (FHR) (during the interval between uterine contractions), long-term variability (normal pattern 95 beat min
91
) and number of tracings with accelerations, early and late decelerations were noted. Variable decelerations were ranked on a scale using the method described by Klavan, Laver and Boscola 6 (mild:decelerations whose nadir 980 beat min Mode of delivery and Apgar scores at 1 and 5 min were recorded. All neonates were examined (general and neurological examinations) 2 h after delivery by a paediatrician who was unaware of patient group assignment.
STATISTICAL METHODS
For all calculations, the Instat computer software package (GraphPad Instat, San Diego, CA, USA) and Solo statistical software (BMDP, Los Angeles, CA, USA) were used. Intragroup comparisons for continuous variables and VAS scores were performed by analysis of variance (ANOVA) for repeated measures, followed by post hoc tests for comparison with baseline (Student-Newman-Keuls multiple comparison test). Significance of differences between groups was tested by analysis of variance for repeated measures (ANOVA). The Mann-Whitney U test was also used for comparison between groups when necessary (loss of subjects in group A after 100 min). To compare the duration of analgesia we used product limit survival analysis (Kaplan-Meier analysis) followed by Wilcoxon's test. Where appropriate, Fisher's exact test was performed. Results are expressed as mean (SD).
Results
The groups were comparable in age, weight at term, weeks of pregnancy, parity, VAS pain scores and stage of cervical dilatation at the time of entry into the study (table 1). All patients enrolled in the study were included in data analysis.
Onset times for analgesia did not differ between groups: 6 (2), 6 (2) and 7 (3) min, respectively, for the control and clonidine 100 g and 150 g groups. Mean duration of anaesthesia was 105 (21) min (range 70-140 min) for patients who did not receive clonidine, and 130 (26) min (range 100-185 min) (P:0.05 vs control) and 144 (40) min (range 100-230 min; P:0.01 vs control, ns vs clonidine 100 g) for patients who received clonidine 100 g and 150 g, respectively. The percentage of patients not requesting additional analgesia was greater in the bupivacaine-clonidine 150 g than in the other fig.1 ). No patient failed to achieve analgesia throughout the study in both groups. Mean VAS scores decreased significantly within 5 min after administration of drug. By 80 min, although both clonidine groups had lower pain scores than the control group, this was not statistically significant until 100 min (table 2) . At 100 and 120 min, pain scores between groups 100 and 150 g were not significantly different. Overall, the degree of maternal and nurse satisfaction was high in all groups. Maternal heart rates were comparable in all three groups before administration of the study drug: 85 (14) beat min 91 for the control group, 82 (12) beat min 91 for the clonidine 100 g group and 86 (11) beat min 91 for the clonidine 150 g group. Atropine was administered for bradycardia in one patient in the clonidine 150 g group.
Mean arterial pressure (MAP) was comparable in all groups at baseline: 87 (10), 90 (13) and 89 (10) mm Hg, respectively. From baseline to time 120 min, there were no significant changes in MAP in the control group, whereas it decreased significantly at 20 min in the clonidine 100 g group (82 (14) mm Hg; P:0.05) ( fig. 2) . From 20 to 140 min this decrease remained significant, being highly significant at 40 min (79 (8) mm Hg; P:0.001). In the clonidine 150 g group, MAP decreased more rapidly (at 5 min: 83 (6) mm Hg; P:0.05) and was highly significant at 20 min (73 (8) mm Hg; P:0.001). In all three groups, MAP was not different over the first 20 min (fig. 2 ).
One patient in the control group, two in the clonidine 100 g group and one in the clonidine 150 g group needed ephedrine for transient hypotension (ns).
There was no change in 2 O p S at any time. Basal ventilatory frequency was comparable between groups and no significant change was noted throughout the study in the control and clonidine 100 g group. In the clonidine 150 g group, there was a significant decrease in ventilatory frequency in the first 80 min: 17 (5) bpm at 40 min vs 21 (3) bpm at baseline (P:0.01). However, inter-group comparisons showed no significant differences over the first 100 min.
In the control group, no patient had a Bromage score exceeding 1. Only one patient in each of the clonidine groups had a score of 2; no patient had Bromage score 3. Sedation scores were comparable between groups. No patient in the control group, one in the clonidine 100 g group and two in the clonidine 150 g group had a sedation score of 3.
Differences in FHR patterns were noted between groups. A decrease in long-term variability (P:0.04) and bradycardia (FHR :120 beat min 91 ) were more usual in the clonidine 150 g group (P:0.02). The numbers of tracings with variable (P:0.01) and late decelerations (P:0.04) were significantly more frequent in the clonidine 150 g group, while early decelerations were more frequent in the clonidine 100 g group. For variable decelerations, five were moderate and two mild in the clonidine 150 g group, four mild and one moderate in the clonidine 100 g group and three moderate and one mild in the Figure 1 Percentage of patients not requesting additional analgesia after extradural injection of 0.0625 % bupivacaine and sufentanil with saline (control) or clonidine 100 g or 150 g (50th percentiles for the three groups were: 100 min for the control group, 120 min for the clonidine 100 g group and 127 min for the clonidine 150 g group). control group. However, no deceleration was classified as severe or needed emergency treatment. The incidence of side effects was low (table 3) . Thirteen patients in the control group had spontaneous vaginal delivery compared with 11 in the clonidine 100 g group and 12 in the clonidine 150 g group (table 1) . Neonatal Apgar scores at 1 and 5 min did not differ between groups and neurological assessments were normal for all babies at 2 h.
Discussion
Local anaesthetics given extradurally are used widely for analgesia in labour. Fentanyl 7 8 and sufentanil 9 are frequently added to local anaesthetic solutions to potentiate their analgesic effects, allowing a reduced local anaesthetic concentration with less motor block [10] [11] [12] . However, the risk of delayed respiratory depression, pruritus and vomiting limits the use of opioids during labour 4 . These adverse effects have stimulated the search for alternative drugs 13 or methods 14 to provide analgesia during labour. We speculated that extradural clonidine, an alpha 2 agonist, might provide effective analgesia when combined with sufentanil and low-dose bupivacaine. Extradurally administered clonidine may be ideally suited for obstetric use because it does not interfere with proprioception and does not induce motor block or respiratory depression 15 16 . After extradural administration, clonidine 300 g alone has been demonstrated to have no effect on fetal physiological indices in sheep 13 . Few studies have assessed the combination of clonidine and local anaesthetics in humans during labour. Brichant and colleagues found that clonidine 75 g was the optimal dose to add to 10 ml of 0.125% bupivacaine, providing a duration of analgesia of 110 min 17 . Compared with 0.125% bupivacaine alone, clonidine 120 g combined with 0.125% bupivacaine increased the mean duration of analgesia from 53 to 110 min; analgesia was unsatisfactory in 15% of the clonidinebupivacaine group compared with 59% in the bupivacaine group 18 . In contrast, a low dose of extradural clonidine (less than 30 g) failed to increase the duration of analgesia of a sufentanil 10 g-0.125% bupivacaine mixture 19 or of 0.125% bupivacaine alone 17 , while Celleno and colleagues 20 showed considerably prolonged analgesia when clonidine 75 g was added to fentanyl 100 g-0.125% bupivacaine (177 vs 89 min). The mean duration of analgesia obtained in our study was approximately 130-140 min, longer than that observed with 0.125% bupivacaine and clonidine alone 17 18 . Our results showed that clonidine 100 and 150 g with a sufentanil 10 g-0.0625% bupivacaine-adrenaline solution significantly improved the duration of analgesia in the first stage of labour.
Analgesia in the control group was satisfactory without any significant change in MAP. Addition of clonidine 100 or 150 g prolonged analgesia but caused significant haemodynamic changes. Comparisons between groups showed that this decrease was more important in the clonidine 150 g group than in the clonidine 100 g group. Extradural clonidine 700 g alone decreased arterial pressure and heart rate in volunteers 15 while minor changes in haemodynamic state were reported with extradural clonidine during pregnancy in a sheep model 3 . Doses of clonidine 30-150 g did not alter haemodynamic state when combined with 0.125% bupivacaine during labour 17 18 and the addition of sufentanil 10 g 19 or fentanyl 50 g 20 to clonidine (30 and 75 g, respectively)-0.125% bupivacaine mixtures did not increase the need for ephedrine treatment during labour. Hypotension during extradural anaesthesia is greater after adrenaline-local anaesthetic solutions than after free adrenaline solution 21 . Extradurally administered clonidine has a U-shaped doseresponse for arterial pressure 15 and may explain the decrease in MAP in our study. Although we observed a decrease in MAP, the change in MAP was modest and the incidence of ephedrine treatment was similar in all groups.
While extradural administration of opioids is associated with respiratory depression 4 , extradural clonidine did not appear to have a marked effect on ventilation. It has been reported that clonidine does not potentiate morphine or alfentanil-induced respiratory depression 22 23 . In this study, although clonidine was combined with sufentanil, no episode of desaturation was noted and ventilatory frequencies did not differ between groups.
An additional side effect of extradural clonidine is sedation 21 . The incidence of sedation was similar between groups in our study. Other side effects were of minor importance.
Approximately 20% of normal gravidas develop fetal heart rate patterns which place the fetus "at risk" during labour. Most frequently, these patterns occur as a result of either umbilical, maternal or uteroplacental circulatory problems 6 . FHR abnormalities such as variable or late decelerations, bradycardia or change in baseline variability may occur. In this study we found that extradural clonidine, particularly clonidine 150 g, was associated with such FHR abnormalities. It is unclear at present if these changes were caused by a direct effect of clonidine on the cardiovascular system of the fetus or an effect on oxygen supply. It has been reported that extradural clonidine 150 g induced serum clonidine concentrations close to 1 ng ml-1 in postoperative patients 24 . In pregnant sheep, clonidine 1 ng ml 91 did not decrease uterine blood flow 13 but a direct effect of such concentrations on fetal and uterine blood flow has not been evaluated in labouring parturients. In contrast, a decrease in long-term variability and bradycardia are expected responses after administration of tranquillizers, clonidine, opioids and extradural local anaesthetics 25 26 . In addition, our clinical study contrasts with those of Cellano and colleagues and O' Meara and Gin who showed no effect of clonidine 150 or 120 g on FHR when given extradurally 18 20 . These differences could be attributed to the different time course of analgesia for the three groups which made intergroup comparisons difficult and to an additional effect of sufentanil on FHR.
